{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:04:50Z","timestamp":1775747090899,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijantimicag.2025.107697","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T16:02:53Z","timestamp":1766592173000},"page":"107697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Enhancing meropenem therapy in critical care: A retrospective study of PK\/PD target attainment and therapeutic drug monitoring"],"prefix":"10.1016","volume":"67","author":[{"given":"Jingli","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7051-7118","authenticated-orcid":false,"given":"Yanfei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8171-9217","authenticated-orcid":false,"given":"Lixia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2025.107697_bib0001","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1007\/s00134-017-4782-4","article-title":"Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: a cluster randomized trial","volume":"43","author":"Bloos","year":"2017","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0002","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejmech.2017.03.022","article-title":"Recent updates of carbapenem antibiotics","volume":"131","author":"El-Gamal","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0003","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.drudis.2020.11.004","article-title":"Oral meropenem for superbugs: challenges and opportunities","volume":"26","author":"Raza","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0004","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/jcpt.13369","article-title":"Meropenem use and therapeutic drug monitoring in clinical practice: a literature review","volume":"46","author":"Steffens","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0005","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.clinthera.2020.02.011","article-title":"Pharmacokinetic and pharmacodynamic characteristics of vancomycin and meropenem in critically ill patients receiving sustained low-efficiency dialysis","volume":"42","author":"Oliveira","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0006","series-title":"Martindale: the complete drug reference","author":"Sweetman","year":"2009"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0007","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1128\/AAC.00997-16","article-title":"Population pharmacokinetics and dosing regimen optimization of meropenem in cerebrospinal fluid and plasma in patients with meningitis after neurosurgery","volume":"60","author":"Lu","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0008","first-page":"385","article-title":"Personalised beta-lactam therapy: basic principles and practical approach","volume":"40","author":"Streit","year":"2016"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0009","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1128\/AAC.02534-17","article-title":"\u03b2-lactam dosage regimens in septic patients with augmented renal clearance","volume":"62","author":"Jacobs","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0010","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0011","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0012","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13613-024-01263-9","article-title":"Prolonged versus intermittent \u03b2-lactam infusion in sepsis: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Zhao","year":"2024","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0013","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jama.2024.9779","article-title":"Continuous vs intermittent \u03b2-lactam antibiotic infusions in critically ill patients with sepsis: the BLING III randomised clinical trial","volume":"332","author":"Dulhunty","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0014","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/jac\/dkx209","article-title":"Too much of a good thing: a retrospective study of \u03b2-lactam concentration-toxicity relationships","volume":"72","author":"Imani","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-020-03397-1","article-title":"Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study","volume":"24","author":"K\u00fchn","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0016","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/14787210.2017.1338139","article-title":"Optimizing \u03b2-lactams treatment in critically-ill patients using pharmacokinetics\/pharmacodynamics targets: are first conventional doses effective?","volume":"15","author":"Delattre","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0017","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0018","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ijantimicag.2016.08.015","article-title":"Optimising meropenem dosing in critically ill Australian indigenous patients with severe sepsis","volume":"48","author":"Tsai","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0019","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1128\/aac.00845-22","article-title":"Population pharmacokinetics\/pharmacodynamics and clinical outcomes of meropenem in critically ill patients","volume":"66","author":"Boonpeng","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0020","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0021","series-title":"Performance Standards for Antimicrobial Susceptibility Testing","year":"2024"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0022","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/23744235.2024.2323002","article-title":"Estimated glomerular filtration rate as a tool for early identification of patients with insufficient exposure to beta-lactam antibiotics in intensive care units","volume":"56","author":"Damgaard","year":"2024","journal-title":"Infect Dis (Lond)"},{"issue":"2 Suppl 1","key":"10.1016\/j.ijantimicag.2025.107697_bib0023","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0024","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0025","first-page":"1313","article-title":"Establishment of f%T>MIC calculation model and optimization of individualized carbapenem antimicrobial therapy for critically ill patients","volume":"53","author":"Chen","year":"2018","journal-title":"Chin J Pharmaceut Sci"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.833189","article-title":"Pharmacodynamic thresholds for beta-lactam antibiotics: a story of mouse versus man","volume":"13","author":"Berry","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0027","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0028","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/17512433.2021.1901574","article-title":"Pharmacokinetic\/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams\/beta-lactamase inhibitors","volume":"14","author":"Gatti","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2025.107697_bib0029","doi-asserted-by":"crossref","first-page":"S994","DOI":"10.1093\/ofid\/ofz415.2487","article-title":"Efficacy and safety of cefiderocol vs. high-dose meropenem in patients with nosocomial pneumonia\u2014results of a phase 3, randomized, multicenter, double-blind, non-inferiority study","volume":"6","author":"Wunderink","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0030","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.4103\/0366-6999.205859","article-title":"Pharmacokinetic and pharmacodynamic efficacies of continuous versus intermittent administration of meropenem in patients with severe sepsis and septic shock: a prospective randomized pilot study","volume":"130","author":"Zhao","year":"2017","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0031","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10096-019-03769-8","article-title":"Diagnostic and medical needs for therapeutic drug monitoring of antibiotics","volume":"39","author":"Mabilat","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0032","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3390\/antibiotics12071112","article-title":"Software- and TDM-guided dosing of Meropenem promises high rates of target attainment in critically ill patients","volume":"12","author":"Chiriac","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0033","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s40266-023-01019-3","article-title":"Safety and tolerability of antimicrobial agents in the older patient","volume":"40","author":"Soraci","year":"2023","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0034","doi-asserted-by":"crossref","first-page":"ofx063","DOI":"10.1093\/ofid\/ofx063","article-title":"Carbapenem-resistant Enterobacteriaceae infections: results from a retrospective series and implications for the design of prospective clinical trials","volume":"4","author":"Alexander","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0035","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3390\/antibiotics11050670","article-title":"C\/MIC>4: a potential instrument to predict the efficacy of meropenem","volume":"11","author":"Zhao","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.833189","article-title":"Pharmacodynamic thresholds for beta-lactam antibiotics: a story of mouse versus man","volume":"13","author":"Berry","year":"2022","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0037","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3143\/geriatrics.52.153","article-title":"Evaluation of antibiotic treatments for urinary tract infections in the elderly, especially regarding the effect on extended spectrum \u03b2-lactamase producing (ESBL-) Escherichia coli: a comparison between meropenem and alternatives","volume":"52","author":"Yamamoto","year":"2015","journal-title":"Jpns J Geriatr."},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-019-2378-9","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care."},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0039","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13054-019-2627-y","article-title":"Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial","volume":"23","author":"Cisneros","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0040","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1128\/AAC.02109-13","article-title":"Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia","volume":"58","author":"Luyt","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0041","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13054-020-2763-4","article-title":"Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial","volume":"24","author":"Ben\u00edtez-Cano","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0042","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jac\/dku354","article-title":"Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study","volume":"70","author":"Frippiat","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0043","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00727-23","article-title":"Individual meropenem epithelial lining fluid and plasma PK\/PD target attainment","volume":"67","author":"Rohani","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0044","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jmii.2019.04.008","article-title":"Comparative efficacy of doripenem versus meropenem for hospital-acquired and ventilator-associated pneumonia","volume":"52","author":"Liu","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0045","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jac\/dku354","article-title":"Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study","volume":"70","author":"Frippiat","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0046","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00228-016-2053-x","article-title":"Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients","volume":"72","author":"Mattioli","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0047","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/phar.2842","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0048","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/cid\/cis856","article-title":"Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomised controlled trial","volume":"56","author":"Dulhunty","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0049","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","article-title":"Beta-lactam Infusion in severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis","volume":"42","author":"Abdul-Aziz","year":"2016","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201667","article-title":"Jiang SJPo. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: a meta-analysis","volume":"13","author":"Yu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0051","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1186\/cc11405","article-title":"Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial","volume":"16","author":"Chytra","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0052","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1586\/14787210.2013.845523","article-title":"Combination therapy for carbapenem-resistant gram-negative bacteria","volume":"11","author":"Zavascki","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0053","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0054","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1089\/sur.2006.063","article-title":"Blood stream infections of abdominal origin in the intensive care unit: characteristics and determinants of death","volume":"9","author":"De Waele","year":"2008","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0055","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00134-020-05950-6","article-title":"Bloodstream infections in critically ill patients: an expert statement","volume":"46","author":"Timsit","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0056","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1128\/AAC.05360-11","article-title":"Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic\/pharmacodynamic target","volume":"56","author":"Martinez","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0057","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.xphs.2024.09.011","article-title":"Population pharmacokinetics and dosing simulations of meropenem in septic critically ill patients with complicated intra-abdominal infection or pneumonia","volume":"114","author":"Huang","year":"2025","journal-title":"J Pharm Sci."},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0058","doi-asserted-by":"crossref","first-page":"1550053","DOI":"10.3389\/fmed.2025.1550053","article-title":"Optimization of meropenem dosing regimens in critically ill patients with augmented renal clearance","volume":"12","author":"Luo","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0059","first-page":"14","article-title":"Prevalence and risk factors of augmented renal clearance: a systematic review and meta-analysis","author":"Hefny","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0060","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/phar.2231","article-title":"Augmented renal clearance","volume":"39","author":"Cook","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0061","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00794-17","article-title":"Population pharmacokinetics of high-dose continuous-infusion meropenem and considerations for use in the treatment of infections due to KPC-producing Klebsiella pneumoniae","volume":"61","author":"Cojutti","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107697_bib0062","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40121-021-00551-2","article-title":"Does prolonged infusion time really improve the efficacy of Meropenem therapy? A prospective study in critically ill patients","volume":"11","author":"Zhao","year":"2022","journal-title":"Infect Dis Ther"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925002523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925002523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:25:37Z","timestamp":1770985537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857925002523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0924857925002523"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107697","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing meropenem therapy in critical care: A retrospective study of PK\/PD target attainment and therapeutic drug monitoring","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107697","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107697"}}